Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.36    
    

CORGENTECH INC.

2003 EQUITY INCENTIVE PLAN  

RESTRICTED STOCK AWARD GRANT NOTICE  

        CORGENTECH INC. (the "Company"), pursuant to its 2003 Equity Incentive Plan (the "Plan"), hereby awards to
Participant the number of shares of the Company's Common Stock set forth below ("Award"). This Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Award
Agreement, the Plan, the form of Assignment Separate from Certificate and the form of Joint Escrow Instructions, all of which are attached hereto and incorporated herein in their entirety. 

	

Participant:	
 	

 
	 	 	

	Date of Grant:	 	 
	 	 	

	Vesting Commencement Date:	 	 
	 	 	

	Number of Shares Subject to Award:	 	 
	 	 	

	Consideration:	 	 
	 	 	

Vesting Schedule: 

[Alternative Vesting Schedules to be Chosen at Time of Grant:

	1.
	100% of the shares shall vest on the Vesting Commencement Date.

 
	2.
	 100% of the shares shall vest on the one year anniversary of the Vesting Commencement Date.

 
	3.
	 50% of the shares shall vest on the one year anniversary of the Vesting Commencement Date and 50% of the shares shall vest on the two year anniversary of the Vesting
Commencement Date.

 
	4.
	 50% of the shares shall vest on the two year anniversary of the Vesting Commencement Date and 50% of the shares shall vest on the three year anniversary of the
Vesting Commencement
Date.]

        Additional Terms/Acknowledgements:    The undersigned Participant acknowledges receipt of, and understands and agrees to, this
Restricted Stock Award Grant Notice, the Restricted Stock Award Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Award Grant Notice, the
Restricted Stock Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of stock in the Company 

1

 

and
supersede all prior oral and written agreements on that subject with the exception of (i) Awards previously granted and delivered to Participant under the Plan, and (ii) the
following agreements only: 

	 
	 	 

	 	OTHER AGREEMENTS:	 	 
	 	 	

	

 	
 	

	CORGENTECH INC.	 	PARTICIPANT:
	

By:	
 	

 	
 	

 	
 	

 
	 	 	
 Signature	 	
 Signature
	

Name:	
 	

John P. McLaughlin	
 	

Name:	
 	

 
	 	 	
	 	 	 	

	

Title:	
 	

President and Chief Executive Officer	
 	

Date:	
 	

 
	 	 	
	 	 	 	

	Date:	 	 	 	 	 	 
	 	 	
	 	 	 	 

        ATTACHMENTS:    Restricted Stock Award Agreement, 2003 Equity Incentive Plan, form of Assignment
Separate from Certificate and form of Joint Escrow Instructions. 

2

 
 
 

ATTACHMENT I
  
    RESTRICTED STOCK AWARD AGREEMENT    
    

3

 
 
 

CORGENTECH INC.
  2003 EQUITY INCENTIVE PLAN    
    

 
 

RESTRICTED STOCK AWARD AGREEMENT    
    

        Pursuant to the Restricted Stock Award Grant Notice ("Grant Notice") and this Restricted Stock Award Agreement (collectively, the "Award") and in consideration of
the Purchase Price (as defined below), Corgentech Inc. (the "Company") has awarded you a restricted stock award under its 2003 Equity Incentive Plan (the "Plan") for the number of shares of the
Company's Common Stock subject to the Award as indicated in the Grant Notice. Defined terms not explicitly defined in this Restricted Stock Award Agreement but defined in the Plan shall have the same
definitions as in the Plan. 

        The
details of your Award are as follows: 

        1.    CONSIDERATION.    The purchase price of Common Stock acquired pursuant to the Award
shall be paid either: (i) in cash at the time of purchase; (ii) at the discretion of the Board, according to a deferred payment or other similar arrangement with you; (iii) at the
discretion of the Board, by services rendered or to be rendered to the Company; or (iv) in any other form of legal consideration that may be acceptable to the Board in its discretion (the
"Purchase Price"); provided, however, that payment of the Common Stock's "par value," as defined in the Delaware General Corporation Law, shall not be
made by deferred payment and must be made in a form of consideration legal under Delaware General Corporation Law. 

        2.    VESTING.    Subject to the limitations contained herein, your Award will vest as
provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. 

        3.    NUMBER OF SHARES.    The number of shares subject to your Award may be adjusted from
time to time for Capitalization Adjustments, as provided in the Plan. 

        4.    TRANSFER RESTRICTIONS.    The shares issued under your Award are not transferable until
vested and while non-vested shall not be sold, assigned, hypothecated, pledged or otherwise transferred by you. The Company shall not be required: (a) to transfer on its books any
shares issued under your Award that are sold, assigned, hypothecated, pledged, or otherwise transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as
owner of such shares issued under your Award or to accord the right to vote as such owner or to pay dividends to any purported transferee of such shares issued under your Award. 

        4.    RIGHT OF REACQUISITION.    

        (a)   The Company shall have the right to reacquire all or any part of the shares (the "Reacquisition Right") you received
pursuant to your Award that have not as yet vested in accordance with the Vesting Schedule on the Grant Notice ("Unvested Shares") on the following terms and conditions: 

          (i)  The Company shall simultaneously with termination of your Continuous Service automatically reacquire all of the Unvested
Shares for the consideration that you paid or for no consideration if the shares were granted to you, unless the Company agrees to waive its Reacquisition Right as to some or all of the Unvested
Shares. Any such waiver shall be exercised by the Company by written notice to you or your representative (with a copy to the Escrow Holder as defined below) within ninety (90) days after the
termination of your Continuous Service, and the Escrow Holder may then release to you the number of Unvested Shares not being reacquired by the Company. If the Company does not waive its Reacquisition
Right as to all of the Unvested Shares, then upon such termination of your Continuous Service, the Escrow Holder shall transfer to the Company the number of shares the Company is reacquiring. 

4

 

         (ii)  The shares issued under your Award shall be held in escrow pursuant to the terms of the Joint Escrow Instructions
attached to the Grant Notice as Attachment IV. You agree to execute three (3) Assignment Separate From Certificate forms (with date and number of shares blank) substantially in the form
attached to the Grant Notice as Attachment III and deliver the same, along with the
certificate or certificates evidencing the shares, for use by the escrow agent pursuant to the terms of the Joint Escrow Instructions. 

       (iii)  Subject to the provisions of your Award, you shall, during the term of your Award, exercise all rights and privileges
of a shareholder of the Company with respect to the shares deposited in escrow. You shall be deemed to be the holder of the shares for purposes of receiving any dividends which may be paid with
respect to such shares and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company's
Reacquisition Right. 

        (iv)  If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the
outstanding stock of the corporation, the stock of which is subject to the provisions of your Award, then in such event any and all new, substituted or additional securities to which you are entitled
by reason of your ownership of the shares acquired under your Award shall be immediately subject to the Reacquisition Right with the same force and effect as the shares subject to this Reacquisition
Right immediately before such event. 

        6.    RESTRICTIVE LEGENDS.    All certificates representing the Common Stock shall have
endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties hereto): 

"THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER'S PREDECESSOR IN INTEREST, A COPY OF WHICH
IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY." 

        7.    AWARD NOT A SERVICE CONTRACT.    Your Award is not an employment or service contract,
and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an
Affiliate to continue your employment. In addition, nothing in your Award shall obligate the Company or an Affiliate, their respective shareholders, boards of directors, Officers or Employees to
continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

        8.    WITHHOLDING OBLIGATIONS.    

        (a)   At the time your Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding
from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax
withholding obligations of the Company or an Affiliate, if any, which arise in connection with your Award. 

        (b)   Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no
obligation to issue a certificate for such shares or release such shares from any escrow provided for herein. 

        9.    TAX CONSEQUENCES.    The acquisition and vesting of the shares may have adverse tax
consequences to you. You may mitigate or exacerbate such tax consequences by filing an election under Section 83(b) of the Internal Revenue Code, as amended (the "Code"). Such election must be
filed within thirty (30) days after the date of your Award. YOU ACKNOWLEDGE THAT IT IS YOUR 

5

 

OWN
RESPONSIBILITY, AND NOT THE COMPANY'S, TO DETERMINE WHETHER A SECTION 83(b) ELECTION IS APPROPRIATE FOR YOUR SITUATION. If YOU DECIDE TO FILE A SECTION 83(b) ELECTION, IT IS YOUR RESPONSIBILITY
AND NOT THE COMPANY'S TO FILE A TIMELY ELECTION UNDER CODE SECTION 83(B), EVEN IF YOU REQUEST THE COMPANY TO MAKE THE FILING ON YOUR BEHALF. 

        10.    NOTICES.    Any notices provided for in your Award or the Plan shall be given in
writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid,
addressed to you at the last address you provided to the Company. 

        11.    MISCELLANEOUS.    

        (a)   The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities,
and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company's successors and assigns. Your rights and obligations under your Award may only be assigned
with the prior written consent of the Company. 

        (b)   You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination
of the Company to carry out the purposes or intent of your Award. 

        (c)   You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice
of counsel prior to executing and accepting your Award and fully understand all provisions of your Award. 

        12.    GOVERNING PLAN DOCUMENT.    Your Award is subject to all the provisions of the Plan,
the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted
pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control. 

6

 
 

ATTACHMENT II
  
    2003 EQUITY INCENTIVE PLAN    
    

 
 

ATTACHMENT III
  
    ASSIGNMENT SEPARATE FROM CERTIFICATE    
    

 
 

ASSIGNMENT SEPARATE FROM CERTIFICATE    
    

        FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Award Grant Notice and Restricted Stock Award
Agreement (the "Award"),                        hereby sells, assigns and transfers unto Corgentech Inc., a Delaware
corporation ("Assignee")                        
(                        ) shares of the common
stock of the Assignee, standing in the undersigned's name on the books of said corporation represented by Certificate No.            herewith and do hereby irrevocably constitute and appoint
                        as attorney-in-fact to transfer the said stock on the books of the within named Company with full power of
substitution in the premises. This Assignment may be
used only in accordance with and subject to the terms and conditions of the Award, in connection with the reacquisition of shares of Common Stock of the Assignee issued to the undersigned pursuant to
the Award, and only to the extent that such shares remain subject to the Assignee's Reacquisition Right under the Award. 

	Dated:	 	 	 	 	 	 	 
	 	 	
	 	 	 	 	 
	

 	
 	

 	
 	

Signature:	
 	

 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

 	
 	

	
, Recipient

        [INSTRUCTION:    Please do not fill in any blanks other than the signature line. The purpose
of this Assignment is to enable the Company to exercise its Reacquisition Right set forth in the Award without requiring additional signatures on your part.] 

 
 

ATTACHMENT IV
  
    JOINT ESCROW INSTRUCTIONS    
    

 
 

JOINT ESCROW INSTRUCTIONS    
    

[Date]

Corporate
Secretary

Corgentech Inc.

650 Gateway Boulevard

South San Francisco, CA 94080 

Dear
Sir/Madam: 

        As
Escrow Agent for both Corgentech Inc., a Delaware corporation (the "Company"), and the undersigned recipient of stock of the Company ("Recipient"), you are hereby authorized
and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Award Grant Notice (the "Grant Notice"),
dated                        to which a copy of these Joint
Escrow Instructions is attached as Attachment IV, and pursuant to the terms of that certain Restricted Stock Award Agreement ("Agreement"), which is Attachment I to the Grant Notice, in accordance
with the following instructions: 

        1.     In the event the Company or an assignee shall elect to exercise the Repurchase Option set forth in the Agreement, the
Company or its assignee will give to Recipient and you a written notice specifying the number of shares of stock to be purchased and the time and place for a closing thereunder. Recipient and the
Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 

        2.     At the closing, you are directed (a) to date the stock assignments necessary for the transfer in question,
(b) to fill in the number of shares being transferred, and (c) to deliver the same, together with the certificate evidencing the shares of stock to be transferred, to the Company against
the simultaneous delivery to you of the purchase price (which may include suitable acknowledgment of cancellation of indebtedness) for the number of shares of stock being purchased pursuant to the
exercise of the Repurchase Option. 

        3.     Recipient irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by
you hereunder and any additions and substitutions to said shares as specified in the Agreement. Recipient does hereby irrevocably constitute and appoint you as his
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities and other property all documents necessary or appropriate to make such
securities negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. 

        4.     This escrow shall terminate upon the exercise in full or expiration of the Repurchase Option, whichever occurs first. 

        5.     If at the time of termination of this escrow you should have in your possession any documents, securities, or other
property belonging to Recipient, you shall deliver all of the same to Recipient and shall be discharged of all further obligations hereunder; provided, however, that if at the time of termination of
this escrow you are advised by the Company that any property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such property to the pledgeholder or
other person designated by the Company. 

        6.     Except as otherwise provided in these Joint Escrow Instructions, your duties hereunder may be altered, amended, modified
or revoked only by a writing signed by all of the parties hereto. 

        7.     You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall
be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be
personally liable for any act you may do or omit to do hereunder as Escrow 

Agent
or as attorney-in-fact for Recipient while acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive
evidence of such good faith. 

        8.     You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other
person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or
comply with any such order, judgment or decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance,
notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction. 

        9.     You shall not be liable in any respect on account of the identity, authorities or rights of the parties executing or
delivering or purporting to execute or deliver these Joint Escrow Instructions or documents or papers deposited or called for hereunder. 

        10.   You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint
Escrow Instructions or any documents deposited with you. 

        11.   Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be Secretary of the Company or if
you shall resign by written notice to each party. In the event of any such termination, the Secretary of the Company shall automatically become the successor Escrow Agent unless the Company shall
appoint another officer or assistant officer of the Company as successor Escrow Agent, and Recipient hereby confirms the appointment of such successor as his attorney-in-fact
and agent to the full extent of your appointment. 

        12.   If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations
in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 

        13.   It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of
possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall
have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no
appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings. 

        14.   All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, and if not during normal business hours of
the recipient, then on the next business day, (c) five (5) calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or
(d) one (1) business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be
sent to the other parties hereto at such party's 

address
set forth below, or at such other address as such party may designate by ten (10) days advance written notice to the other parties hereto. 

	Company:	 	Corgentech Inc.

650 Gateway Boulevard

South San Francisco, CA 94080

Attn: General Counsel / Chief Financial Officer
	
Recipient:	
 	

 
	 	 	

	 	 	

	 	 	

	
Escrow Agent:	
 	

Corgentech Inc.

650 Gateway Boulevard

South San Francisco, CA 94080

Attn: Corporate Secretary

        15.   By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow
Instructions; you do not become a party to the Grant Notice. 

        16.   You shall be entitled to employ such legal counsel and other experts (including, without limitation, the firm of Cooley
Godward llp) as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and you may pay such counsel reasonable
compensation therefor. The Company shall be responsible for all fees generated by such legal counsel in connection with your obligations hereunder. 

        17.   This instrument shall be binding upon and inure to the benefit of the parties hereto and their respective successors and
permitted assigns. It is understood and agreed that references to "you" and "your" herein refer to the original Escrow Agent and to any and all successor Escrow Agents. It is understood and agreed
that the Company may at any time or from time to time assign its rights under the Grant Notice and these Joint Escrow Instructions in whole or in part. 

        18.   These Joint Escrow Instructions shall be governed by and interpreted and determined in accordance with the laws of the
State of California, as such laws are applied by California courts to contracts made and to be performed entirely in California by residents of that state. 

	 	 	 	 	Very truly yours,
	

 	
 	

 	
 	
CORGENTECH INC.
	

 	
 	

 	
 	

By:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

Name:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

Title:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	
RECIPIENT
	

 	
 	

 	
 	

	

 	
 	

 	
 	

Name:	
 	

 
	 	 	 	 	 	 	

	ESCROW AGENT:	 	 	 	 
	

	
 	

 	
 	

 
	

NAME:	
 	

 	
 	

 	
 	

 
	 	 	
	 	 	 	 

QuickLinks

Exhibit 10.36

ATTACHMENT I RESTRICTED STOCK AWARD AGREEMENT

CORGENTECH INC. 2003 EQUITY INCENTIVE PLAN

RESTRICTED STOCK AWARD AGREEMENT

ATTACHMENT II 2003 EQUITY INCENTIVE PLAN

ATTACHMENT III ASSIGNMENT SEPARATE FROM CERTIFICATE

ASSIGNMENT SEPARATE FROM CERTIFICATE

ATTACHMENT IV JOINT ESCROW INSTRUCTIONS

JOINT ESCROW INSTRUCTIONSQuickLinks
 -- Click here to rapidly navigate through this document

  

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  

  
 

    Exhibit 10.37    
    

THIS
AGREEMENT is made this 27th day of December, 2004 between: 

	(1)
	CORGENTECH INC., a Delaware corporation having its principal place of business at 650 Gateway Boulevard, South San Francisco, CA 94080,
USA ("Corgentech"); and

	(2)
	AVECIA LIMITED, a company incorporated in England and Wales under registered number 3730853 and whose registered office is at Hexagon
House, Blackley, Manchester, M9 8ZS, England ("Avecia"). 

WHEREAS

	A.
	Corgentech
is in the business of developing and manufacturing the Products (as defined below).

	B.
	Avecia
has experience and knowledge with regard to process development and manufacture of [*], and has performed
development and manufacturing services relating to the Products for Corgentech.

	C.
	In
consideration of the [*] payment by Corgentech of the purchase price for the Products, Avecia undertakes to
manufacture the Products at its Grangemouth, Scotland facility during the [*] production schedule set forth in the Programme (as
defined below), and to comply with the other terms and conditions set forth in this Agreement. 

1

 

NOW
IT IS HEREBY AGREED AS FOLLOWS: 

1.     Definitions: 

	1.1
	In
this Agreement and the Schedules attached hereto, the following expressions shall have the following meanings: 

	Affiliate	 	any corporation, association or other business entity which directly or indirectly controls, is controlled by or is under common control with Avecia or Corgentech.
	
Background Intellectual Property	
 	

any Intellectual Property owned by or in the possession of a party (and to which that party has the necessary rights) at the date of this Agreement or Intellectual Property developed independently of the Programme by any employee of that party
without reference to any of the Confidential Information disclosed by the other party, provided that, Confidential Information and Intellectual Property disclosed to Avecia or licensed by Corgentech to Avecia [*]
Avecia Background Intellectual Property for purposes of this Agreement and Confidential Information and Intellectual Property disclosed to Corgentech or licensed by Avecia to Corgentech [*]
Corgentech Background Intellectual Property for purposes of this Agreement.
	
Commencement Date	
 	

27 December 2004
	
Completion	
 	

completion of the Programme as defined in Section 2.2(d).
	
Confidential Information	
 	

any technical and commercial information relating to the Products or the Programme and any other information of a confidential nature disclosed (whether disclosed in writing, verbally, by way of sample or by any other means and whether directly or
indirectly) by either party ("the Disclosing Party") to the other ("the Receiving Party") and whether before, on or after the Commencement Date, including and without limitation, any information relating to the Disclosing Party's business
affairs.
	
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
	 	 	 

2

 

	
Force Majeure	
 	

any cause beyond the reasonable control of the party in question which for the avoidance of doubt and without prejudice to the generality of the foregoing shall include governmental actions, war, riots, terrorism, fire, flood, but shall not include
failure of the Product in clinical trials or failure of the Product to gain regulatory approval.
	
GMP	
 	

current good manufacturing practice and standards as provided for (and as amended from time to time) in European Community Directive 91/356/EEC (Principles and guidelines of good manufacturing practice for medicinal products) and in the Current Good
Manufacturing Practice Regulations to the US Code of Federal Regulations Title 21 (21 CFR 210 and 21 CFR 211) in relation to the production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by ICH Harmonised
Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7A.
	
Intellectual Property	
 	

all know-how, inventions, discoveries, devices, data, patents, designs, copyrights, or other industrial or intellectual property and all applications therefor.
	
Joint Inventions	
 	

New Intellectual Property invented jointly by the parties.
	
New Intellectual Property	
 	

Intellectual Property arising during and as a direct result of the parties carrying out the Programme.
	
Product	
 	

the single strand intermediates and/or hybridized duplex products set forth in Part A of Schedule 1, and "the Products" shall mean any or all of them together.
	
Programme	
 	

the programme of work to be carried out under this Agreement described in Part B of Schedule 1 (including the Specifications), or as may be amended from time to time in writing signed by each of the parties.
	
Programme Amendment Order	
 	

means a document detailing changes to the Programme agreed and signed by both parties.
	
Specification	
 	

the specification for each of the Products more particularly described in Part B of Schedule 1.
	
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
	 	 	 

3

 

	
Technology Transfer	
 	

the documentation by Avecia of the manufacture of the Products, and the transfer of production from Avecia's Grangemouth facility pursuant to Section 2.4.
	
Third Party	
 	

any person or entity other than Avecia or Corgentech or their respective Affiliates.

	1.2
	Any
reference to "day" or "days" means any day other than a Saturday, Sunday or Bank Holiday in the United Kingdom. 

2.     Performance of the Programme  

	2.1
	Quality
Assurance.    Avecia will carry out the work as detailed in the Programme in accordance with GMP and consistent with the provisions of a
Quality Agreement to be mutually agreed upon by the parties within [*].

	2.2
	Programme
Details.    In consideration of the [*] by Corgentech of the
purchase price of the Products in accordance with the schedule set forth in Section 3 below:

	(a)
	Avecia
shall use its reasonable commercial efforts to manufacture the Products, in accordance with the production schedule and specific requirements detailed in Part B of
Schedule 1.

	(b)
	In
the event a batch of Product produced by Avecia does not meet the relevant Specification, the parties shall decide whether the  [*] in order [*] the
Specification. If the parties agree
that the [*], such agreement shall be recorded in writing. If a batch of Product produced by Avecia does not meet the relevant
Specification, Avecia shall use its reasonable commercial efforts to replace such batch, from production at Avecia's Grangemouth or Milford, Massachusetts facility, at  [*] to Corgentech, within
[*] after notice from
Corgentech of such failure to meet the relevant Specification. If a batch of Product meets the relevant Specification (whether  [*] under this paragraph or otherwise) Avecia shall deliver to Corgentech,
a sample of each non-GMP batch and each
batch of Product produced in accordance with GMP.

	(c)
	Avecia
shall package and deliver the Products in accordance with Section 4 below.

	(d)
	The
Programme shall be deemed to be complete when all batches of the Products produced under the Programme have been delivered to Corgentech or its designee under Section 4.

	2.3
	Technical
Assistance.    During the Programme and for [*] following
Completion, Avecia will offer reasonable assistance to Corgentech in respect of Corgentech's regulatory filing activities for the Product both during and after Completion, subject to payment by
Corgentech of Avecia's reasonable costs and expenses in providing these consultancy services.

	2.4
	Termination
of Production and Technology Transfer.    Upon completion of the Programme, but in no event later than March 31, 2005,
Corgentech shall notify Avecia of its intention to continue future manufacturing and production of the Products at Avecia's Grangemouth facility ("Grangemouth"). In the event Corgentech notifies
Avecia that Corgentech intends to continue future manufacturing and production at Avecia's Grangemouth facility 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

4

 

the
parties shall negotiate in good faith an agreement governing such production within [*] after such notification. In the
event Corgentech notifies Avecia that it does not intend to continue production at Grangemouth, Avecia shall cooperate fully in the documentation of all manufacturing and production processes related
to the Programme and the manufacture of the Products, including the Technical Information (as defined below) ("the Technology Transfer Documentation") and communication and delivery to Corgentech of
the Technology Transfer Documentation. As part of the Technology Transfer, Avecia: (a) will deliver all equipment and assets belonging to Corgentech to Corgentech's facility or as it may
direct, and (b) hereby grants to Corgentech a royalty-free, irrevocable, perpetual, non-exclusive, world-wide license, with power to sub-license,
under all New Intellectual Property owned by Avecia pursuant to Section 5.3 below to make, use, sell, offer for sale, import, keep and otherwise deal in the Products. "Technical Information"
shall include, but not be limited to, all know-how, experience, instructions, standards, methods, test and trial results, manufacturing processes, hazard assessments, registration data,
quality control standards, formulae, Specifications, storage data, samples, drawings, designs, descriptions of packaging materials and all other relevant information relating to the Products or the
design, manufacture or storage of the Products. In consideration for the technical consultancy services relating to the Technology Transfer to Corgentech, Corgentech shall pay Avecia's reasonable
costs of producing the documentation and transferring the assets associated with the Business from the Grangemouth facility to Corgentech (or as it shall direct), for an agreed period, not to exceed  [*]. Avecia and Corgentech shall each use their reasonable efforts to determine the cost of the Technology Transfer before  [*]. 

3.     Payments  

	
3.1
	Manufacturing
 Services Fees. 
	(a)
	In
consideration of Avecia: (i) manufacturing, selling and delivering the Products and undertaking related activities, as more particularly described in the Programme set forth
in Part B of Schedule 1; and (ii) continuing production at its Grangemouth facility, Corgentech shall [*]
the purchase price for the Products, payable as set forth in the following table in three (3) installments. Installments 1, 2 and 3 shall be as set forth in the following table. These amounts
do not include [*], which shall be [*]. 

        Purchase Price  

	Installment
 
	 	Amount (U.S.$)
	 	Activity
	 	Payment

Date

	

1	
 	
[*]	
 	

Programme commencement and [*] as set forth in Schedule 1	
 	
[*]
	

2	
 	
[*]	
 	
[*] as set forth in Schedule 1	
 	
[*]
	

3	
 	
[*]	
 	
[*] as set forth in Schedule 1	
 	
[*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

5

 

	(a)
	Avecia
hereby represents and warrants to Corgentech that the information disclosed to Corgentech detailing Avecia's cost of production (including employee costs, rent, utilities, and
all other fixed costs as summarized on Schedule 2) are true, complete and accurate as of the date hereof.

	(b)
	Avecia
hereby undertakes that the Purchase Price set forth in Section 3.1 above shall be [*] the
appropriate [*] of Avecia's fixed costs [*], in the
event Avecia [*] commences production, manufacturing or development activities  [*] using [*]weeks 
[*] in the Programme during the term of this Agreement. Such fixed costs shall be
[*] Corgentech [*] the  [*] weeks [*] their  [*] with Avecia. Any such [*] Purchase Price paid or
payable by Corgentech under this Section 3.1 shall be immediately [*] Corgentech or, at Corgentech's option,  [*] payments to Avecia. In no event shall
any [*]  installment payable hereunder by Corgentech [*].

	3.2
	Bank
Account Details.    Unless otherwise notified by Avecia, all amounts payable to Avecia under this Agreement shall be paid in U.S. Dollars,
without deduction, by telegraphic transfer to [*].

	3.3
	Value
Added Tax.    All sums payable under this Agreement are stated exclusive of any VAT which may be payable and which shall be for the
account of Corgentech. In the event that Corgentech fails to export the Product within the period set out in Clause 4.3 below, Avecia shall be entitled to issue an invoice for VAT payable in
respect of the price paid for such un-exported Product and Corgentech shall pay such invoice within [*] of receipt
thereof. 

4.     Delivery of Product  

	4.1
	Delivery
of Material.    Delivery of the Products will be made [*]
Avecia's Grangemouth facility (Incoterms 2000). Products shall be delivered on the due date set forth in the table in Schedule 1 or such other date as shall be agreed in writing by the parties.

	4.2
	Packing
and Shipping.    Avecia shall arrange for packing of the material to be delivered under Section 4.1 and shall comply with all
reasonable requirements of Corgentech in packing the material. Risk of loss in, and title to, each shipment of Product shall pass to Corgentech under this Agreement  [*].

	4.3
	Export
and Storage.    Corgentech shall export from the United Kingdom the Product delivered to it under Clause 4.1  [*]. Notwithstanding the foregoing and subject to
Clause 3.3, upon Corgentech's prior written request and agreement in
writing of the terms of such storage including, without limitation, conditions, fees, risk and duration, Avecia shall store the Products  [*]. 

5.     Intellectual Property  

	5.1
	Ownership
of Background Intellectual Property.    Nothing in this Agreement shall affect the ownership by either party of its Background
Intellectual Property.

	5.2
	Licence
to Intellectual Property for the Programme.    Corgentech grants to Avecia a non-exclusive, non-transferable,
non-assignable, royalty-free licence to use Corgentech's Background Intellectual Property and Corgentech's New Intellectual Property whilst this Agreement remains in force for
the purpose of carrying out the Programme. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

6

 

	5.3
	Ownership
of New Intellectual Property.    New Intellectual Property shall be owned by the party inventing such New Intellectual Property as
determined under applicable laws. The parties shall jointly own all right, title and interest in and to any and all Joint Inventions.

	5.4
	Joint
Inventions    The following provisions shall apply in respect of Joint Inventions:

	(a)
	Each
party will promptly disclose all Joint Inventions to the other party. Each party shall take all necessary actions to vest title to all Joint Inventions (including all
intellectual property rights therein) in both parties. The parties shall agree which party shall assume responsibility for the preparation, filing, prosecution and maintenance of all registered
intellectual property covering Joint Inventions, using attorneys reasonably acceptable to both parties, and both parties shall participate and cooperate in such preparation, filing, prosecution and
maintenance. Unless otherwise agreed, the parties shall share equally the expenses of such preparation, filing, prosecution and maintenance.

	(b)
	If
the parties agree that one of the party's in-house attorneys shall be used to obtain and maintain any registered intellectual property rights, neither that party ("the
Relevant Party") nor any of its employees, servants or agents shall be liable for any damage or loss suffered by the other party as a result of any action or inaction on the part of the Relevant Party
or its employees, servants or agents in the course of the filing, prosecution or maintenance of any such registered intellectual property rights.

	(c)
	Each
party may [*] use, license and otherwise commercially exploit, and transfer its share of, Joint Inventions  [*] by either party, provided that any transfer
shall be notified to the other party, and be subject to the preservation of the
rights and obligations of this Agreement with respect of Joint Inventions.

	(d)
	The
parties shall determine on a case by case basis which of the parties shall be primarily responsible for the enforcement and defence of the parties' rights in any Joint Invention
and the other party shall fully cooperate in such defence and enforcement including, if necessary, joining as a party to such action and/or furnishing a power of appointment. Unless otherwise agreed,
the enforcement and defence of such Joint Inventions.

	(e)
	If,
at any time, a party does not wish to share, or continue to share in the costs associated with obtaining or maintaining any registered intellectual property rights for any Joint
Invention, then that party shall transfer all rights in those registered intellectual property rights to the other party at [*]
to the other party, but at the other party's [*], provided the other party wishes to maintain such registered intellectual
property rights. The party which has transferred its rights shall have [*] in such registered intellectual property rights, save
that such party shall, if it so requests, be [*]. Such  [*] shall be [*] which  [*]
. If neither party wishes to maintain such registered intellectual property rights in any or all countries then they shall
agree to abandon such registered intellectual property rights in the country or countries concerned.

	(f)
	In
the event that the parties are unable to agree on any matter relating to a Joint Invention, then the matter shall be referred to the Vice-President, Biotechnology at
Avecia and the CEO at Corgentech. If agreement cannot be reached by the Vice-President, Biotechnology at Avecia and the CEO at Corgentech within  [*] of referral, then either party may refer the matter
to arbitration under clause 19.3.

	5.5
	Licences
under New Intellectual Property. 
	(a)
	Corgentech
hereby grants to Avecia a [*] non-exclusive, world-wide licence, with power
to sub-license, under New Intellectual Property owned by Corgentech under Clause 5.3 for use other than to use, sell, offer for sale, import, keep and otherwise deal in the
Products.

	(b)
	Avecia
hereby grants to Corgentech a [*] non-exclusive, world-wide licence, with power
to sub-license, under New Intellectual Property owned by Avecia under Clauses 5.3 to make, use, sell, offer for sale, import, keep and otherwise deal in the Products. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

7

 

	5.6
	[*] Access to Avecia Background Intellectual Property. 

	(a)
	Avecia
shall not [*] in respect of Avecia's use of Background Intellectual Property to manufacture the Product
under this Agreement or any future supply agreement in addition to the [*] the Programme set out in this Agreement or  [*] the Product agreed under such
future supply agreement.

	(b)
	If
Corgentech or a designee requires a licence under Avecia's Background Intellectual Property in order to manufacture the Product, then such licence shall be granted to Corgentech or
such designee by Avecia subject to [*] between Corgentech and Avecia. Any such  [*]. 

6.     Warranties, Liability and Indemnity  

	6.1
	General
Warranty. 
	(a)
	Each
party warrants to the other that it has the necessary right and authority to enter into this Agreement and that to the best of its knowledge at the date of this Agreement it is
the rightful owner or licensee of all Background Intellectual Property;

	(b)
	Each
party warrants to the other that to the best of its knowledge at the date of this Agreement, the use of Background Intellectual Property made available by it to the other party
pursuant to this Agreement for the purposes set out in this Agreement will not infringe the Intellectual Property of a Third Party; and

	(c)
	Avecia
warrants to Corgentech that all Products delivered hereunder will (i) conform strictly to the Specifications and other requirements set forth in Part B of
Schedule 1; and (ii) shall be manufactured in compliance with all applicable laws, rules and regulations.

	6.2
	Intellectual
Property Indemnity.    Each party ("the First Party") shall be liable for and
indemnify the other ("the Second Party") against any liability, loss, claim, damage, proceedings and costs whatsoever arising out of any actual or
suspected infringement of any Third Party Intellectual Property (an "IP Infringement") as a result of the Second Party's use in its performance of this
Agreement of the Background Intellectual Property provided by the First Party, provided that the Second Party:

	(a)
	gives
the First Party the sole conduct of the defence to any claim or action in respect of the IP Infringement and does not at any time admit liability or otherwise settle or
compromise or attempt to settle or compromise the said claim or action except upon the express instructions of the First Party; and

	(b)
	acts
in accordance with the reasonable instructions of the First Party and gives the First Party such assistance as it shall reasonably require in respect of the conduct of such
defence. 

Notwithstanding
the foregoing provisions of this Clause 6.2, the First Party's liability to indemnify the Second Party shall cease in respect of continuing use by the Second Party of the
Background Intellectual Property which is the subject of the IP Infringement following either: 

          (i)  notification
(which shall be given promptly) by the First Party to the Second Party that the Background Intellectual Property provided by the First Party is actually or
is believed by the First Party to be the subject of an IP Infringement; or 

         (ii)  the
Second Party becoming aware that the Background Intellectual Property provided by the First Party is the subject of an IP Infringement. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

8

 

	6.3
	Liability
for the Product.    Avecia shall not have any liability whatsoever resulting from, and Corgentech shall fully indemnify Avecia against
all claims, suits, actions, demands, liabilities, expenses and/or losses (including reasonable legal fees) brought or suffered by Corgentech or any Third Party brought or made against Avecia, its
directors, officers or employees, and against all costs incurred in connection therewith, arising out of or resulting from the use of the Product following delivery.

	6.4
	Liability
for the Technical Information.    Liability in respect of use or operation of the Technical Information (or any part of the Technical
Information), by or on behalf of Corgentech shall rest solely on Corgentech, except to the extent that Avecia is required to indemnify Corgentech in accordance with Clause 6.2 above or except
to the extent that such liability arises from a Third Party claim for property damage or personal injury arising from Avecia's failure to operate the Technical Information in accordance with mutually
agreed batch records and standard procedures or methods. Corgentech shall indemnify Avecia against any liability, loss, damages, costs, legal costs, professional and other expenses whatsoever incurred
or suffered by Avecia arising out of or in respect of use or operation of the Technical Information (or any part of the Technical Information) by or on behalf of Corgentech except to the extent that
Avecia is required to indemnify Corgentech in accordance with Clause 6.2 above or except to the extent that such loss, damages, costs, legal costs, professional and other expenses arise from a
Third Party claim for property damage or personal injury arising from Avecia's failure to operate the Technical Information in accordance with mutually agreed batch records.

	6.5
	Limitation
on Liability.    Subject to the provisions of Clause 6.6, Avecia's  [*] liability (whether for breach of contract, negligence, breach of statutory duty and/or other tort, or
otherwise) in
connection with or as a result of the work carried out under this Agreement shall be [*], subject to  [*] in any [*].

	6.6
	No
Liability for Indirect Losses.    Neither party shall be liable to the other for any indirect, consequential or special loss, loss of profits
or damage suffered by the other howsoever arising. 

7.     Confidentiality  

	7.1
	Maintenance
of Confidentiality.    In consideration of the Disclosing Party disclosing the Confidential Information to the Receiving Party, the
Receiving Party hereby undertakes to maintain confidential all such Confidential Information, and it will accordingly not directly or indirectly use any of the Confidential Information in whole or in
part save for the purposes envisaged in this Agreement, nor will it disclose any of the Confidential Information to any Affiliate or Third Party.

	7.2
	Exceptions.    The
foregoing restrictions on the Receiving Party shall not apply to any Confidential Information which:

	(a)
	the
Receiving Party can prove was already in its possession and at its free disposal before the disclosure hereunder to it;

	(b)
	is
hereafter disclosed to, purchased or otherwise legally acquired by the Receiving Party by or from a Third Party who has not derived it directly or indirectly from the Disclosing
Party under an obligation of confidentiality; 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

9

 

	(c)
	is
or becomes available to the public whether in printed publications or otherwise through no act or default on the part of the Receiving Party; or

	(d)
	the
Receiving Party can prove to the reasonable satisfaction of the Disclosing Party has been developed independently of the Programme (including, for purposes of this
Section 7.2 development or manufacture of the Products prior to the date hereof) by the Receiving Party without reference to any of the Confidential Information disclosed by the Disclosing
Party.

	7.3
	Disclosure
to Affiliates.    Either party may disclose Confidential Information to or via an Affiliate, provided that the party making any such
disclosure shall, prior to such disclosure, ensure each Affiliate to which Confidential Information is to be disclosed is made aware of the obligations contained in this Agreement and agrees to be
subject to confidentiality obligations no less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality contained in this agreement by such Affiliate shall be
treated as a breach of such obligations by the party making the disclosure to the Affiliate.

	7.4
	Survival
of Obligations.    The provisions of this Section 7 shall survive termination or expiry of this Agreement and shall continue for
a period of [*] from the date of termination or expiry. 

8.     Duration and Termination

	8.1
	Duration.    This
Agreement shall be deemed to have commenced on the Commencement Date and shall continue until Completion unless terminated in
accordance with the provisions of Section 8.2.

	8.2
	Termination.    Subject
to Section 9, this Agreement may be terminated as follows:

	(a)
	by
either party forthwith if the other shall fail to pay its debts as they fall due or if a liquidator, receiver, manager or administrator is appointed over the business or assets of
the other, and otherwise upon thirty days' notice at any time prior to Completion; or

	(b)
	by
either party forthwith if the other is in breach of this Agreement and does not rectify such breach within  [*] of receipt of written notice form the first party requiring rectification of the breach,
provided that it is intended that
the parties will discuss any alleged breach and its remediation as soon as it is known. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  

10

 

 9.     Consequences of Termination  

	9.1
	Consequences.    In
the event of termination under Section 8.2(b) above, Avecia shall refund to Corgentech any monies paid to Avecia,
less an agreed sum in respect of work done by Avecia and not affected by the breach, taking into consideration the payments set out in Section 3 in respect of such unaffected work and in the
absence of agreement upon such sum the provisions of Section 19 shall apply. Avecia shall forthwith deliver all product, materials and work in progress to Corgentech or to such person or
facility as it shall direct.

	9.2
	Acquired
Rights.    Termination or expiry of this Agreement, for whatever reason, shall not prejudice the acquired rights of either party.

	9.3
	Survival.    The
provisions of Sections 3, 5, 6, 7-9, 11-17 and 19 shall survive the termination or expiry of this
Agreement. 

10.   Independent Contractor  

Nothing
in this Agreement shall create, or be deemed to create, a partnership or the relationship of principal and agent or employer and employee between the parties. Each party agrees to perform
under this Agreement solely as an independent contractor. 

11.   Entire Agreement  

This
Agreement contains the entire agreement between the parties and supersedes any previous agreements relating to the Programme and any understandings between the parties with respect thereto. 

12.   Announcements and Publicity  

Any
public disclosure by Avecia or its Affiliates regarding the existence or terms of this Agreement, the Programme or methods for making, using or manufacturing the Product shall require the prior
written consent of Corgentech. 

13.   Assignment  

This
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective legal successors but shall not otherwise be assignable by either party without the prior
written consent of the other party, which consent shall not be unreasonably withheld, provided that either party may assign this Agreement without consent by notice in writing to the other party to a
purchaser or assignee of the whole or part of the business to which this Agreement relates. 

14.   Variation  

No
variation or amendment of this Agreement shall bind either party unless made in writing in the English language and agreed to in writing by duly authorised officers of both parties. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

11

 

15.   Illegality  

If
any provision of this Agreement is agreed by the parties to be illegal, void or unenforceable under any law that is applicable hereto or if any court of competent jurisdiction in a final decision
so determines, this Agreement shall continue in force save that such provision shall be deemed to be excised herefrom with effect from the date of such agreement or decision or such earlier date as
the parties may agree. 

16.   Waiver  

A
failure by either party hereto to exercise or enforce any rights conferred upon it by this Agreement shall not be deemed to be a waiver of any such rights or operate so as to bar the exercise or
enforcement thereof at any subsequent time or times. 

17.   Notices and Communications  

Any
notice required or permitted under this Agreement shall be in writing which may take the form of a letter or facsimile and shall be sent by prepaid post, facsimile, or hand delivery (including
messenger service). The addresses for any such notice or other communication shall be those stated on the first page of this Agreement (unless otherwise changed by notice in writing to the other
party) and shall be marked for the attention of the Vice-President, Biotechnology in the case of Avecia and the CEO in the case of Corgentech. 

18.   Force Majeure  

Neither
party shall be liable to the other party in any manner whatsoever for any failure or delay in performing its obligations under this Agreement if and to the extent, and for the duration, that
such failure or delay is due to Force Majeure. Without prejudice to Section 8, any said failure or delay shall
not give either party the right to terminate this Agreement except, and to the extent that such Force Majeure continues for a period exceeding  [*]. 

19.   Law and Jurisdiction  

	19.1
	Governing
Law.    This Agreement is governed by and shall be construed and interpreted in accordance with the laws of  [*]. Any proceedings between the parties shall be conducted in the
English language.

	19.2
	Reference
to Parties' Senior Representatives.    Prior to any dispute, difference or disagreement concerning this Agreement proceeding to
litigation to arbitration or through the courts the parties shall seek to resolve the matter within [*] by referring it to the
Vice-President, Avecia Biotechnology and the CEO of Corgentech.

	19.3
	Arbitration.    Any
matter or dispute arising out of or in connection with this Agreement which is not able to be resolved pursuant to
Clause 19.2 shall be finally settled by commercial arbitration to be held in [*]. In appointing arbitrators, the parties
shall consider the appointment of an arbitrator or arbitrators capable of making decisions on the technical aspects of the Validation Programme.

	19.4
	Interim
Steps.    Neither of the parties shall be deemed to be precluded from taking such interim formal steps as may be considered necessary
to protect such party's position while the procedures referred to in Clauses 20.2 and 20.3 are pursued.

	19.5
	Other
Proceedings.    In the event that the matter or dispute remains unresolved by such commercial arbitration within  [*] of commencement of such procedure, then the parties shall be
at liberty to take such other proceedings (as defined below) as
they think fit.

	19.6
	Jurisdiction.    Except
as provided for in Clauses 19.2, 19.3 and 19.4, in relation to any legal action or proceedings to enforce this
Agreement or arising out of in connection with this Agreement ("proceedings") each of the parties irrevocably submits to the exclusive jurisdiction of the Courts of  [*]. 

        IN
WITNESS WHEREOF, the authorised representatives of the parties have executed this Agreement on the date written at the top of this Agreement. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

12

 

	 
	 	 
	 	 
	 	 

	For and on behalf of CORGENTECH INC.	 	For and on behalf of AVECIA LIMITED
	

Signature	
 	

/s/  J. X. REGAN      
	
 	

Signature	
 	

/s/  KEVIN COX      

	

Name	
 	

J.X. Regan
	
 	

Name	
 	

Kevin Cox

	

Position	
 	

VP Manufacturing
	
 	

Position	
 	

VP Biotechnology

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  

13

  

 
 

Schedule 1  
    

 
 

PART A—THE PRODUCTS  
    

E2F
single strand intermediates

NFkB single strand intermediates and hybridized duplex products

HIF-1 alpha single strand intermediates 

 
 

PART B—THE PROGRAMME  
    

(Attached)

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

14

 

[*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

15

 

1.     Request for Proposal  

        Corgentech have requested that Avecia provide a proposal for the supply of [*]. The
product is to be suitable for use in [*]. 

2.     Project Scope  

2.1   Product Description  

Product
[*]

Description [*].

Sequence [*]

Product [*]

2.2   Product Specification  

According
to current PDF. 

2.3   Project Structure  

        [*]

3.     Project Assumptions  

	 
	 	Assumptions

	Pricing	 	— [*]
	 	 	— [*]
	

Material Use	
 	

— [*]
	

Timelines	
 	

— [*]
	 	 	— [*]
	

Shipping terms	
 	

— [*]
	

Stability	
 	

— [*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

16

 

4.     Facilities  

        Avecia will use the Manufacturing Facility at Grangemouth Scotland. 

5.     Compliance  

Material
will be GMP and will be suitable for use in human clinical trials. 

6.     Raw Materials  

Avecia
will source materials from approved suppliers. 

7.     Financial Summary  

The
price for cGMP project activities, manufacture of [*]. 

[*]. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

17

 

8.     Milestone Payments  

	Proposed Milestone
	 	Estimated Timing
	 	Payment

	[*]	 	[*]	 	[*]
	
[*]	
 	
[*]	
 	
[*]
	

 	
 	

Total	
 	
[*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

18

 
 
 

Schedule 2  
    

 
 

AVECIA's COSTS  
    

(ATTACHED)  

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

19

 

[*]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

20

QuickLinks

Exhibit 10.37

Schedule 1

PART A—THE PRODUCTS

PART B—THE PROGRAMME

Schedule 2

AVECIA's COSTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]